Last updated: 2026-09-16 09:46:00. Prices reflect the latest pre-market trading data. Stock price data is sourced from Massive.
Arvinas, Inc. (ARVN) operates in the PHARMACEUTICAL PREPARATIONS sector and is listed on NASDAQ. The stock is currently priced at $8.26, with a market capitalisation of $549.24M and a P/E ratio of 58.07. Over the past 52 weeks, its price has ranged from $6.97 to $14.51. This page covers its latest market performance, valuation, price trends and company information.
$549.24M | |
$8.26 | |
$108.47 | |
$5.90 | |
$8.26 | |
4.00 | |
802.33K | |
58.07 | |
$14.51 | |
$6.97 | |
-- | |
-- |
Arvinas, Inc. (ARVN) is trading at $8.26 in pre-market trading as of 2026-09-16 08:12:00, down 0.06% ($0.00) from the previous close of $8.26
Pre-market trading shows how investors are pricing ARVN before the regular session opens. The current pre-market price is near the previous close, indicating cautious early trading sentiment.
Over the past seven days, Arvinas, Inc. (ARVN) moved from $9.39 to $8.26, representing a decline of 12.09% ($1.13).
The stock traded between $8.09 and $9.46 during the period. The latest price is near the lower end of the 7-day range, indicating strong downward.
The average daily volume was 1.06 million shares, up versus the previous seven-day period, indicating higher trading activity.
Position in Range: 17.0%
ARVN is currently trading at $8.26, placing it 17.0% of the way from its 52-week low of $6.97 to its 52-week high of $14.51. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
Arvinas Inc is a clinical-stage biotechnology company focused on improving the lives of patients suffering from debilitating and life-threatening diseases through the discovery, development, and commercialization of therapies that degrade disease-causing proteins. The company is using its PROteolysis TArgeting Chimera, a protein degradation platform, to develop therapeutics designed to harness the body's own natural protein disposal system to selectively and efficiently degrade and remove disease-causing proteins. Its clinical development program includes various product candidates such as ARV-102, ARV-806, ARV-393, ARV-027, and vepdegestrant, in their different stages of development, being developed to target certain harmful proteins causing oncology and neurology-related diseases.
| Industry | PHARMACEUTICAL PREPARATIONS |
| Employees | 246 |
| Exchange | NASDAQ |
| Company Website |
Eligible investors can buy real shares of Arvinas, Inc. (ARVN) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.